Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China
· Delayed Price · Currency is CNY 6.58
+0.03 (0.46%)
Apr 29, 2026, 3:00 PM CST
SHA:600223 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 187.75 | 243.53 | 303.39 | 45.46 | 361.9 | Upgrade
|
| Depreciation & Amortization | 108.6 | 102.23 | 147.76 | 121.6 | 94.03 | Upgrade
|
| Other Amortization | 15.37 | 11.08 | 10.01 | 8.01 | 7.91 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.06 | -0.96 | 0.77 | -0.77 | 0.15 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.17 | 0.7 | 2.19 | 4.74 | 4.04 | Upgrade
|
| Loss (Gain) From Sale of Investments | -55.39 | -63.98 | -214.34 | -116.21 | -201.34 | Upgrade
|
| Provision & Write-off of Bad Debts | 10.27 | 25.94 | 38.31 | 66.86 | 101.05 | Upgrade
|
| Other Operating Activities | 59.91 | 82.83 | 162.9 | 684.2 | 335.79 | Upgrade
|
| Change in Accounts Receivable | -87.79 | 175.89 | 1,861 | 523.12 | 2,032 | Upgrade
|
| Change in Inventory | 119.35 | -33.91 | -598.86 | 1,899 | 344.74 | Upgrade
|
| Change in Accounts Payable | -80.34 | -308.12 | -1,228 | -2,238 | 3,760 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | - | 5.59 | Upgrade
|
| Operating Cash Flow | 276.22 | 228.65 | 474.15 | 998.1 | 6,848 | Upgrade
|
| Operating Cash Flow Growth | 20.80% | -51.78% | -52.49% | -85.42% | 53.96% | Upgrade
|
| Capital Expenditures | -110.42 | -157.22 | -211.37 | -166.11 | -281.53 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.08 | 0.33 | 3.89 | 5.7 | 0.61 | Upgrade
|
| Divestitures | -11.26 | 2,982 | 2,641 | - | 33.05 | Upgrade
|
| Investment in Securities | 0.06 | 11.68 | 177.52 | 30.83 | -268.32 | Upgrade
|
| Other Investing Activities | 62.15 | 155.85 | 62.69 | 130.81 | 64.38 | Upgrade
|
| Investing Cash Flow | -59.38 | 2,993 | 2,673 | 1.24 | -451.81 | Upgrade
|
| Long-Term Debt Issued | 296.32 | 348 | 2,701 | 12,621 | 9,931 | Upgrade
|
| Total Debt Issued | 296.32 | 348 | 2,701 | 12,621 | 9,931 | Upgrade
|
| Long-Term Debt Repaid | -457.35 | -2,235 | -5,281 | -13,161 | -15,351 | Upgrade
|
| Total Debt Repaid | -457.35 | -2,235 | -5,281 | -13,161 | -15,351 | Upgrade
|
| Net Debt Issued (Repaid) | -161.03 | -1,887 | -2,580 | -540.61 | -5,420 | Upgrade
|
| Issuance of Common Stock | - | - | - | 22.47 | 17.05 | Upgrade
|
| Common Dividends Paid | -65.19 | -183.57 | -487.96 | -1,175 | -2,015 | Upgrade
|
| Other Financing Activities | -20.94 | -35.02 | -29.69 | 75.44 | 629.44 | Upgrade
|
| Financing Cash Flow | -247.16 | -2,106 | -3,097 | -1,618 | -6,789 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.01 | -0.23 | -1.01 | 9.82 | -0.41 | Upgrade
|
| Net Cash Flow | -30.33 | 1,116 | 48.93 | -608.61 | -393.24 | Upgrade
|
| Free Cash Flow | 165.8 | 71.44 | 262.79 | 831.98 | 6,567 | Upgrade
|
| Free Cash Flow Growth | 132.10% | -72.82% | -68.41% | -87.33% | 53.04% | Upgrade
|
| Free Cash Flow Margin | 4.54% | 1.79% | 5.74% | 6.42% | 53.12% | Upgrade
|
| Free Cash Flow Per Share | 0.16 | 0.07 | 0.26 | 0.73 | 6.35 | Upgrade
|
| Cash Interest Paid | 1.17 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 277.93 | 290.52 | 553.18 | 1,099 | 1,786 | Upgrade
|
| Levered Free Cash Flow | 73.02 | 3,106 | 2,879 | 1,837 | 2,779 | Upgrade
|
| Unlevered Free Cash Flow | 76.67 | 3,120 | 2,939 | 2,088 | 2,849 | Upgrade
|
| Change in Working Capital | -50.53 | -172.71 | 23.18 | 184.2 | 6,145 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.